Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir

S. Safrin, T. Schacker, J. Delehanty, E. Hill, L. Corey

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

The thiocarbonohydrazone 348U87 inactivates herpes simplex virus ribonucleotide reductase and potentiates the activity of acyclovir against wild-type and acyclovir-resistant strains of herpes simplex virus. We treated 10 human immunodeficiency virus-infected patients with acyclovir-resistant anogenital herpes simplex virus infection with a topical preparation of 348U87 (3%) in combination with acyclovir (5%) in an open-labelled study. Transient improvement with combination therapy occurred frequently; however, target lesions reepithelialized completely in only 1 of 10 patients. Termination of study drug therapy was most often due to cessation of therapeutic effect before complete resolution of lesions. As currently formulated, topical 348U87 offers little therapeutic benefit for this indication.

Original languageEnglish (US)
Pages (from-to)975-979
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume37
Issue number5
DOIs
StatePublished - 1993

Fingerprint Dive into the research topics of 'Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir'. Together they form a unique fingerprint.

Cite this